Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

123.29 -2.71 (-2.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,141,434
Open 125.91
Bid (Size) 123.00 (5)
Ask (Size) 124.49 (1)
Prev. Close 126.00
Today's Range 122.68 - 126.51
52wk Range 75.92 - 173.25
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire

Performance

YTD
+28.15%
+28.15%
1 Month
+3.81%
+3.81%
3 Month
-12.34%
-12.34%
6 Month
-8.70%
-8.70%
1 Year
+58.04%
+58.04%

More News

Read More
Peeling Back The Layers: Exploring Sarepta Therapeutics Through Analyst Insights
Via Benzinga
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Unveiling 15 Analyst Insights On Sarepta Therapeutics
Via Benzinga
Analyst Scoreboard: 12 Ratings For Sarepta Therapeutics
Via Benzinga
Unveiling 26 Analyst Insights On Sarepta Therapeutics
Via Benzinga
How Is The Market Feeling About Sarepta Therapeutics?
Via Benzinga
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
Via Benzinga
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
Via Investor's Business Daily
2 High-Flying Growth Stocks With Massive Upside Potential
Via The Motley Fool
Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
Via The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
A Closer Look at 28 Analyst Recommendations For Sarepta Therapeutics
Via Benzinga
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
Via MarketBeat
Exposures Product Safety
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
From Sarepta Therapeutics, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
From Sarepta Therapeutics, Inc.
Via Business Wire
These 2 Biotech Stocks Are Set to Soar
Via The Motley Fool
Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
From Sarepta Therapeutics, Inc.
Via Business Wire
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
Via Benzinga
Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building
Via Investor's Business Daily
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Sarepta Therapeutics, Inc.
Via Business Wire
This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?
Via MarketBeat
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.